Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach

Table 1 Inhibition of cell growth by NVP-LAQ824 and NVP-LBH589

Cell line	IC50 (μmol/L)
	NVP-LAQ824		NVP-LBH589
	3 d	6 d	3 d	6d
TFK-1	0.06	0.05	0.01	0.01
EGI-1	0.07	0.05	0.01	0.01
CC-LP-1	0.05	0.02	0.01	0.01
CC-SW-1	0.13	0.05	0.04	0.01
Sk-ChA-1	0.21	0.08	0.15	0.04
Mz-ChA-1	0.14	0.07	0.09	0.04
Mz-ChA-2	0.10	0.04	0.02	0.01

Table 2 Cell cycle analysis (mean ± SD, %)

	MZ-CHA-2			EGI-1
	G0/G1	S	G2/M	G0/G1	S	G2/M
CTRL	38.3 ± 3	44.7 ± 3	17.0 ± 3	58.7 ± 5	29.2 ± 2	12.1 ± 1
LAQ824 (25 nmol/L)	37.0 ± 1	42.8 ± 2	20.1 ± 2	50.1 ± 7	31.9 ± 4	18.1 ± 3
LAQ824 (50 nmol/L)	36.9 ± 2	38.7 ± 5	24.4 ± 4	41.2 ± 2	34.8 ± 2	24.1 ± 4
LBH589 (25 nmol/L)	35.5 ± 1	27.6 ± 3	36.9 ± 2	38.8 ± 5	33.8 ± 3	27.4 ± 4
LBH589 (50 nmol/L)	38.8 ± 2	9.0 ± 3	52.3 ± 2	46.0 ± 1	15.1 ± 2	38.9 ± 1

Table 3 MIB-1- and TUNEL-staining of mouse tumor specimens (mean, %)

	MZ-CHA-2		EGI-1
	MIB-1	Apoptosis	MIB-1	Apoptosis
CTRL	85	0.1	38	4.3
GEM	77	2.2	29	6.5
LBH	62	2.9	26	5.9
COMBO	67	7.8	17	9.0